Advertisements
Feeds:
Posts
Comments

Posts Tagged ‘computational biology’


The Vibrant Philly Biotech Scene: Focus on Computer-Aided Drug Design and Gfree Bio, LLC

Curator and Interviewer: Stephen J. Williams, Ph.D.

 

 

philly philly2night

 

 

 

 

 

 

 

This post is the second in a series of posts highlighting interviews with Philadelphia area biotech startup CEO’s and show how a vibrant biotech startup scene is evolving in the city as well as the Delaware Valley area. Philadelphia has been home to some of the nation’s oldest biotechs including Cephalon, Centocor, hundreds of spinouts from a multitude of universities as well as home of the first cloned animal (a frog), the first transgenic mouse, and Nobel laureates in the field of molecular biology and genetics. Although some recent disheartening news about the fall in rankings of Philadelphia as a biotech hub and recent remarks by CEO’s of former area companies has dominated the news, biotech incubators like the University City Science Center and Bucks County Biotechnology Center as well as a reinvigorated investment community (like PCCI and MABA) are bringing Philadelphia back. And although much work is needed to bring the Philadelphia area back to its former glory days (including political will at the state level) there are many bright spots such as the innovative young companies as outlined in these posts.

efavirenz_med-2In today’s post, I had the opportunity to talk with molecular modeler Charles H. Reynolds, Ph.D., founder and CEO of Gfree Bio LLC, a computational structure-based design and modeling company based in the Pennsylvania Biotech Center of Bucks County. Gfree is actually one of a few molecular modeling companies at the Bucks County Biotech Center (I highlighted another company RabD Biotech which structural computational methods to design antibody therapeutics).

Below is the interview with Dr. Reynolds of Gfree Bio LLC and Leaders in Pharmaceutical Business Intelligence (LPBI):

LPBI: Could you briefly explain, for non-molecular modelers, your business and the advantages you offer over other molecular modeling programs (either academic programs or other biotech companies)? As big pharma outsources more are you finding that your company is filling a needed niche market?

GfreeBio: Gfree develops and deploys innovative computational solutions to accelerate drug discovery. We can offer academic labs a proven partner for developing SBIR/STTR proposals that include a computational or structure-based design component. This can be very helpful in developing a successful proposal. We also provide the same modeling and structure-based design input for small biotechs that do not have these capabilities internally. Working with Gfree is much more cost-effective than trying to develop these capabilities internally. We have helped several small biotechs in the Philadelphia region assess their modeling needs and apply computational tools to advance their discovery programs. (see publication and collaboration list here).

LPBI: Could you offer more information on the nature of your 2014 STTR award?

GfreeBio: Gfree has been involved in three successful SBIR/STTR awards in 2014.   I am the PI for an STTR with Professor Burgess of Texas A&M that is focused on new computational and synthetic approaches to designing inhibitors for protein-protein interactions. Gfree is also collaborating with the Wistar Institute and Phelix Therapeutics on two other Phase II proposals in the areas of oncology and infectious disease.

LPBI: Why did you choose the Bucks County Pennsylvania Biotechnology Center?

GfreeBio: I chose to locate my company at the Biotech Center because it is a regional hub for small biotech companies and it provides a range of shared resources that are very useful to the company. Many of my most valuable collaborations have resulted from contacts at the center.

LPBI: The Blumberg Institute and Natural Products Discovery Institute has acquired a massive phytochemical library. How does this resource benefit the present and future plans for GfreeBio?

GfreeBio: To date Gfree Bio has not been an active collaborator with the Natural Products Insititute, but I have a good relationship with the Director and that could change at any time.

LPBI: Was the state of Pennsylvania and local industry groups support GfreeBio’s move into the Doylestown incubator? Has the partnership with Ben Franklin Partners and the Center provided you with investment and partnership opportunities?

GfreeBio: Gfree Bio has not been actively seeking outside investors, at least to date. We have been focused on growing the company through collaborations and consulting relationships. However, we have benefitted from being part of the Keystone Innovation Zone, a state program that provides incentives for small technology-based businesses in Pennsylvania.

LPBI: You will be speaking at a conference in the UK on reinventing the drug discovery process through tighter collaborations between biotech, academia, and non-profit organizations.  How do you feel the Philadelphia area can increase this type of collaboration to enhance not only the goals and missions of nonprofits, invigorate the Pennsylvania biotech industry, but add much needed funding to the local academic organizations?

GfreeBio: I think this type of collaboration across sectors appears to be one of the most important emerging models for drug discovery.   The Philadelphia region has been in many ways hard hit by the shift of drug discovery from large vertically integrated pharmaceutical companies to smaller biotechs, since this area was at the very center of “Big Pharma.” But I think the region is bouncing back as it shifts more to being a center for biotech. The three ingredients for success in the new pharma model are great universities, a sizeable talent pool, and access to capital. The last item may be the biggest challenge locally. The KIZ program (Keystone Innovation Zone) is a good start, but the region and state could do more to help promote innovation and company creation. Some other states are being much more aggressive.

LPBI: In addition, the Pennsylvania Biotechnology Center in Bucks County appears to have this ecosystem: nonprofit organizations, biotechs, and academic researchers. Does this diversity of researchers/companies under one roof foster the type of collaboration needed, as will be discussed at the UK conference? Do you feel collaborations which are in close physical proximity are more effective and productive than a “virtual-style” (online) collaboration model? Could you comment on some of the collaborations GfreeBio is doing with other area biotechs and academics?

GfreeBio: I do think the “ecosystem” at the Pennsylvania Biotechnology Center is important in fostering new innovative companies. It promotes collaborations that might not happen otherwise, and I think close proximity is always a big plus. As I mentioned before, many of the current efforts of Gfree have come from contacts at the center.   This includes SBIR/STTR collaborations and contract work for local small biotech companies.

LPBI: Thompson Reuters just reported that China’s IQ (Innovation Quotient) has risen dramatically with the greatest patents for pharmaceuticals and compounds from natural products. Have you or your colleagues noticed more competition or business from Chinese pharmaceutical companies?

GfreeBio: The rise of Asia, particularly China, has been one of the most significant recent trends in the pharmaceutical industry. Initially, this was almost exclusively in the CRO space, but now China is aggressively building a fully integrated domestic pharmaceutical industry.

LPBI: How can the Philadelphia ecosystem work closer together to support greater innovation?

GfreeBio: A lot has happened in recent years to promote innovation and company creation in the region. There could always be more opportunities for networking and collaboration within the Philadelphia community. Of course the biggest obstacle in this business is often financing. Philadelphia needs more public and private sources for investment in startups.

LPBI: Thank you Dr. Reynolds.

Please look for future posts in this series on the Philly Biotech Scene on this site

Also, if you would like your Philadelphia biotech startup to be highlighted in this series please contact me: sjwilliamspa@comcast.net or @StephenJWillia2.
Our site is read by ~ 570,000 readers, among them thousand international readers daily and followed by thousands of Twitter followers.

 

Other posts on this site in this VIBRANT PHILLY BIOTECH SCENE SERIES OR referring to PHILADELPHIA BIOTECH include:

RAbD Biotech Presents at 1st Pitch Life Sciences-Philadelphia

The Vibrant Philly Biotech Scene: Focus on Vaccines and Philimmune, LLC

What VCs Think about Your Pitch? Panel Summary of 1st Pitch Life Science Philly

1st Pitch Life Science- Philadelphia- What VCs Really Think of your Pitch

LytPhage Presents at 1st Pitch Life Sciences-Philadelphia

Hastke Inc. Presents at 1st Pitch Life Sciences-Philadelphia

PCCI’s 7th Annual Roundtable “Crowdfunding for Life Sciences: A Bridge Over Troubled Waters?” May 12 2014 Embassy Suites Hotel, Chesterbrook PA 6:00-9:30 PM

Pfizer Cambridge Collaborative Innovation Events: ‘The Role of Innovation Districts in Metropolitan Areas to Drive the Global an | Basecamp Business

Mapping the Universe of Pharmaceutical Business Intelligence: The Model developed by LPBI and the Model of Best Practices LLC

Advertisements

Read Full Post »


Preface to Metabolomics as a Discipline in Medicine

Author: Larry H. Bernstein, MD, FCAP

 

The family of ‘omics fields has rapidly outpaced its siblings over the decade since
the completion of the Human Genome Project.  It has derived much benefit from
the development of Proteomics, which has recently completed a first draft of the
human proteome.  Since genomics, transcriptomics, and proteomics, have matured
considerably, it has become apparent that the search for a driver or drivers of cellular signaling and metabolic pathways could not depend on a full clarity of the genome. There have been unresolved issues, that are not solely comprehended from assumptions about mutations.

The most common diseases affecting mankind are derangements in metabolic
pathways, develop at specific ages periods, and often in adulthood or in the
geriatric period, and are at the intersection of signaling pathways.  Moreover,
the organs involved and systemic features are heavily influenced by physical
activity, and by the air we breathe and the water we drink.

The emergence of the new science is also driven by a large body of work
on protein structure, mechanisms of enzyme action, the modulation of gene
expression, the pH dependent effects on protein binding and conformation.
Beyond what has just been said, a significant portion of DNA has been
designated as “dark matter”. It turns out to have enormous importance in
gene regulation, even though it is not transcriptional, effected in a
modulatory way by “noncoding RNAs.  Metabolomics is the comprehensive
analysis of small molecule metabolites. These might be substrates of
sequenced enzyme reactions, or they might be “inhibiting” RNAs just
mentioned.  In either case, they occur in the substructures of the cell
called organelles, the cytoplasm, and in the cytoskeleton.

The reactions are orchestrated, and they can be modified with respect to
the flow of metabolites based on pH, temperature, membrane structural
modifications, and modulators.  Since most metabolites are generated by
enzymatic proteins that result from gene expression, and metabolites give
organisms their biochemical characteristics, the metabolome links
genotype with phenotype.

Metabolomics is still developing, and the continued development has
relied on two major events. The first is chromatographic separation and
mass  spectroscopy (MS), MS/MS, as well as advances in fluorescence
ultrasensitive optical photonic methods, and the second, as crucial,
is the developments in computational biology. The continuation of
this trend brings expectations of an impact on pharmaceutical and
on neutraceutical developments, which will have an impact on medical
practice. What has lagged behind, and may continue to contribute to the
lag is the failure to develop a suitable electronic medical record to
assist the physician in decisions confronted with so much as yet,
hidden data, the ready availability of which could guide more effective
diagnosis and management of the patient. Put all of this together, and
we can meet series challenges as the research community
interprets and integrates the complex data they are acquiring.

.

Read Full Post »


RAbD Biotech Presents at 1st Pitch Life Sciences-Philadelphia-September 16, 2014

RAbD is a new biotechnology company founded by Fox  Chase Cancer Center investigators Gregory Adams, Ph.D., Matthew Robinson, Ph.D. and Roland Dunbrack, Ph.D. that is focused on the knowledge-based design of antibodies that bind to key functional, often highly conserved and difficult to target epitopes. We are using homology modeling, crystal structures, protein docking and design software and algorithms to drive combinatorial sampling of CDRs to computationally design new antibodies and then express, validate and perform further design in an iterative manner.Brian Smith, Ph.D., MBA is RAbD Biotech’s Business Development Lead.

Contact information for RAbD Biotech:

Website  http://rabdbiotech.com/

LinkedIn

Twitter @RAbDBiotech

The overall goal of RAbD is to

“drug the undruggable”

The company using in silico design methods to design to produce novel antibodies and biomimetics. The company is developing a first in class biomimetic, RaD-003, for the treatment of ovarian cancer.  Ovarian  cancer is one of the most deadly of all women’s cancers, with very low 5 year survival rates.  An expected 22,000 US women a year will be diagnosed and expected 16,000 will die every year.  Cisplatin/paclitaxel therapy is only approved and effective chemotherapy for ovarian cancer yet resistance develops quickly and is common. RaD-003  targets the MISII receptor (Mullerian Inhibiting Substance Type II Receptor), which is expressed on ovarian cancer cells but not on normal ovarian epithelium.

It has been shown that activation of this receptor by the Mullerian Inhibiting Substance (MIS) has antitumor activity in ovarian cancer.

The MISII receptor had been considered undruggable as

  • MIS is too expensive and difficult to produce
  • previous attempts to develop therapeutic antibodies ot MISIIR have proven difficult

Therefore, the company used their computational platform to produce a “first in class” chimeric biomimetic to more effectively target and activate MISIIR.

For  more information about this meeting and the Mid-Atlantic Bioangels and 1st Pitch please see posting on this site

Read Full Post »


Metabolomic analysis of two leukemia cell lines. II.

Larry H. Bernstein, MD, FCAP, Reviewer and Curator

Leaders in Pharmaceutical Intelligence

 

In Part I of metabolomics of two leukemia cell lines, we have established a major premise for the study, an insight into the use of an experimental model, and some insight into questions raised.

I here return to examine these before pursuing more detail in the study.

Q1. What strong metabolic pathways come into focus in this study?

Answer – The aerobic and anaerobic glycolytic pathways, with a difference measured in the extent of participation of mitochondrial oxidative phosphorylation.

Q2. Would we expect to also gain insight into the effect, on balance, played by a suppressed ubiquitin pathway?

Answer – lets look into this in Part II.

Q3. Would the synthesis of phospholipid and the maintenance of membrane structures requires availability of NADPH, which would be a reversal of the TCA cycle at the cost of delta G in catabolic energy, be consistent with increased dependence of anaerobic glycolysis  with unchecked replication?

Answer: Part II might show this, as the direction and the difference between the cell lines is consistent with a Warburg (Pasteur) effect.

Recall the observation that the model is based on experimental results from  lymphocytic leukemia cell lines in cell culture.  The internal metabolic state is inferred from measurement of external metabolites.

The classification of the lymphocytic leukemias in humans is based on T-cell and B-cell lineages, but actually uses cell differentiation (CD) markers on the cytoskeleton for recognition.  It is only a conjecture that if the cells line were highly anaplastic, they might not be sustainable in cell culture in perpetuity.
The analogue of these cells to what I would expect to see in humans is the SLL having the characteristic marking: CD5, see http://www.pathologyoutlines.com/topic/lymphomaSLL.html

Micro description
=======================================================

● Effacement of nodal architecture by pale staining pseudofollicles or proliferation centers with ill-defined borders, containing small round mature lymphocytes, prolymphocytes (larger than small lymphocytes, abundant basophilic cytoplasm, prominent nucleoli), paraimmunoblasts (larger cells with distinct nucleoli) and many smudge cells
● Pseudofollicular centers are highlighted by decreasing light through the condenser at low power; cells have pale cytoplasm but resemble soccer balls or smudge cells on peripheral smear (cytoplasm is bubbly in mantle cell lymphoma); may have plasmacytoid features
● May have marginal zone, perifollicular or interfollicular patterns, but these cases also have proliferation centers (Mod Pathol 2000;13:1161)
● Interfollicular pattern: large, reactive germinal centers; resembles follicular lymphoma but germinal centers are bcl2 negative and tumor cells resemble SLL by morphology and immunostains
(Am J Clin Path 2000;114:41)
● Paraimmunoblastic variant: diffuse proliferation of paraimmunoblasts (normally just in pseudoproliferation centers); rare, <30 reported cases; usually multiple lymphadenopathies and rapid disease progression; case report in 69 year old man (Hum Pathol 2002;33:1145); consider as mantile cell lymphoma if t(11;14)(q13;q32) is present; may also represent CD5+ diffuse large B cell lymphoma
Bone marrow: small focal aggregates of variable size with irregular, poorly circumscribed outlines; lymphocytes are well differentiated, small, round with minimal atypia; may have foci of transformation; rarely has granulomas (J Clin Pathol 2005;58:815)
● Marrow infiltrative patterns are also described as diffuse (unmutated IgH genes, ZAP-70+, more aggressive), nodular (associated with IgH hypermutation, ZAP-70 negative) or mixed (variable mutation of IgH, variable ZAP-70, Hum Pathol 2006;37:1153)

 

Positive stains
=======================================================

● CD5, CD19, CD20 (dim), CD23, surface Ig light chain, surface IgM (dim)
● Also CD43, CD79a, CD79b (dim in 20%, Arch Pathol Lab Med 2003;127:561), bcl2
● Variable CD11c, FMC7 (42%)
Negative stains
=======================================================

● CD10, cyclin D1
Molecular
=======================================================

● Trisomy 12 (30%, associated with atypical CLL and CD79b), deletion 13q14 (25-50%),
deletion of 11q23 (worse prognosis, 10-20%)

 

Results

We set up a pipeline that could be used to

  • infer intracellular metabolic states from semi-quantitative data
  • regarding metabolites exchanged between cells and their environment.

Our pipeline combined the following four steps:

  1. data acquisition,
  2. data analysis,
  3. metabolic modeling and
  4.  experimental validation of
  • the model predictions (Fig. 1A).

We demonstrated the pipeline and the predictive potential

  • to predict metabolic alternations in diseases such as cancer
  • based on two lymphoblastic leukemia cell lines.

The resulting Molt-4 and CCRF-CEM condition-specific cell line models were able

  • to explain metabolite uptake and secretion
  •  by predicting the distinct utilization of central metabolic pathways by the two cell lines.

Whereas the CCRF-CEM model

  • resembled more a glycolytic, commonly referred to as ‘Warburg’ phenotype,
  • our predictions suggested  a more respiratory phenotype for the Molt-4  model.

We found these predictions to be in agreement with measured gene expression differences

  • at key regulatory steps in the central metabolic pathways, and
  • they were also consistent with  data regarding the energy and redox states of the cells.

After a brief discussion of the data generation and analysis steps, the results

  • derived from model generation and analysis will be described in detail.

 

2.1 Pipeline for generation of condition-specific metabolic cell line models

2.1.1 Generation of experimental data

We monitored the growth and viability of lymphoblastic leukemia cell lines in
serum- free medium (File S2, Fig. S1). Multiple omics  data sets  were derived  from these cells.

Extracellular metabolomics (exo-metabolomic) data,

  • comprising measurements of the metabolites in the spent medium of the cell cultures
    (Paglia et al. 2012a),
  • were collected along with transcriptomic data, and
  • these data sets were used to construct the models.

 

2.1.4 Condition-specific models for CCRF-CEM and Molt-4 cells

To determine whether we had obtained two distinct models,

  • we evaluated the reactions, metabolites, and genes of the two models.

Both the Molt-4 and CCRF-CEM models contained approximately

  • half of the reactions and metabolites present in the global model (Fig. 1C).

They were very similar to each other in terms of their

  • reactions,
  • metabolites, and
  • genes (File S1, Table S5A–C).

The Molt– 4 model contained

  • seven reactions that were not present in the CCRF-CEM model
    (Co-A biosynthesis pathway and exchange reactions).

In contrast, the CCRF-CEM  contained

31 unique reactions

  • arginine and proline metabolism,
  • vitamin B6  metabolism,
  • fatty acid activation,
  • transport, and exchange reaction.
  • There  were 2 and 15 unique metabolites in the Molt-4 and CCRF-CEM models,  respectively
    (File S1, Table S5B).
    Approximately three quarters of the global  model  genesremained in the condition-specific cell line models  (Fig. 1C).

The Molt-4 model contained

  • 15 unique genes, and

the CCRF-CEM model had

  • 4 unique genes (File S1, Table S5C).

Both models lacked NADH dehydrogenase
(complex I of the electron transport chain—ETC),

  •  determined by  the  absence of expression of a mandatory subunit
    (NDUFB3, Entrez gene ID 4709).

The ETC was fueled by FADH2 originating from

  1. succinate dehydrogenase and
  2. from fatty acid oxidation, which
  • through flavoprotein electron transfer
  • could contribute to the same ubiquinone pool as
  • complex I and complex II (succinate dehydrogenase).

Despite their different in vitro growth rates
(which differed by 11 %, see File S2, Fig. S1) and

  • differences in exo-metabolomic data (Fig. 1B) and
  • transcriptomic data,
  • the internal networks were largely conserved
  • in the two condition-specific cell line models.

 

2.1.5 Condition-specific cell line models predict distinct metabolic strategies

Despite the overall similarity of the metabolic models,

  • differences in their cellular uptake and secretion patterns suggested
  • distinct metabolic states in the two cell lines
    (Fig. 1B and see “Materials and methods” section for more detail).

To interrogate the metabolic differences, we sampled the solution space

  • of each model  using an Artificial Centering Hit-and-Run (ACHR) sampler (Thiele et al. 2005).

For this  analysis, additional constraints were applied, emphasizing

  • the  quantitative differences in commonly uptaken and secreted metabolites.

The  maximum possible uptake and maximum possible secretion flux rates were

  • reduced according to the measured relative differences between the cell lines
    (Fig. 1D, see “Materials and methods” section).

We plotted the number of sample points containing a particular flux rate for each reaction. The resulting

  • binned histograms can be understood as representing the probability that
  • a particular reaction can have a certain flux value.

A comparison of the sample points obtained for the Molt-4 and CCRF-CEM models revealed

  • a  considerable shift in the distributions, suggesting
  • a higher utilization of  glycolysis by the CCRF-CEM model (File S2, Fig. S2).

This result  was further  supported by differences

  • in medians calculated from sampling points (File S1,  Table S6).

The shift persisted throughout all reactions of the pathway and

  • was  induced by the higher glucose uptake (35 %) from
  • the extracellular medium in CCRF-CEM cells.

The sampling median for glucose uptake was 34 % higher

  • in the  CCRF-CEM model than in Molt-4 model (File S2, Fig. S2).

The usage of the  TCA cycle was also distinct in the two condition-specific cell-line models (Fig. 2).

  • the models used succinate dehydrogenase differently (Figs. 23).

The Molt-4 model utilized an associated reaction to generate FADH2, whereas

  • in  the CCRF-CEM model, the histogram was shifted in the opposite direction,
  • toward  the generation of succinate.

Additionally, there was a higher efflux of  citrate toward

  • amino acid and lipid metabolism in the CCRF-CEM model (Fig. 2).

There was higher flux through anaplerotic and cataplerotic reactions

  • in the CCRF-CEM model than in the Molt-4 model (Fig. 2);
  • these reactions include the efflux  of citrate through

 

  1. ATP-citrate lyase,
  2. uptake of glutamine,
  3. generation of  glutamate from glutamine,
  4. transamination of pyruvate and
  5.  glutamate to alanine  and to 2-oxoglutarate,
  6. secretion of nitrogen, and
  7. secretion of alanine.

The Molt-4 model showed higher utilization of oxidative phosphorylation (Fig. 3),

  • supported by elevated median flux through ATP synthase (36 %) and other  enzymes,
  • which contributed to higher oxidative metabolism.

The sampling  analysis therefore revealed different usage of

  • central metabolic pathways by the condition-specific models.

 

Fig. 2

Differences in the use of the TCA cycle by the CCRF-CEM

Differences in the use of the TCA cycle by the CCRF-CEM

Differences in the use of the TCA cycle by the CCRF-CEM model (red) and the Molt-4 model (blue).
The table provides the median values of the sampling results. Negative values in histograms and Table

  • describe reversible  reactions with flux in the reverse direction.

There are multiple reversible  reactions for the transformation of

  1. isocitrate and α-ketoglutarate,
  2. malate and  fumarate, and
  3. succinyl-CoA and succinate.

These reactions are  unbounded,  and therefore histograms are not shown.
The details of participating cofactors  have been removed.

Atp ATP, cit citrate, adp ADP, pi phosphate, oaa oxaloacetate, accoa acetyl-CoAcoa coenzyme-A,
icit isocitrate, αkg α-ketoglutarate, succcoa succinyl-CoAsucc succinate, fumfumarate, mal malate,
oxa oxaloacetate,  pyr pyruvate, lac lactate, ala alanine, gln glutamine, ETC electron transport  chain.

 

Electronic supplementary material The online version of this article
http://dx.doi.org:/10.1007/s11306-014-0721-3 
contains supplementary material,  which  is available to authorized users.

  1.  K. Aurich _ G. Paglia _ O ´ . Rolfsson _ S. Hrafnsdo´ ttir _
  2. Magnu´sdo´ ttir _ B. Ø. Palsson _ R. M. T. Fleming _ I. Thiele. Center for Systems Biology,
    University of Iceland, Reykjavik, Iceland
  3.  K. Aurich _ R. M. T. Fleming _ I. Thiele (&). Luxembourg Centre for Systems Biomedicine,
    University of Luxembourg, Campus Belval, Esch-Sur-Alzette, Luxembourg
    e-mail: ines.thiele@uni.lu
  4. M. Stefaniak. School of Health Science, Faculty of Food Science and Nutrition,
    University of Iceland, Reykjavik, Iceland
  5. Ø. Palsson. Department of Bioengineering, University of California San Diego, La Jolla, CA, USA

http://link.springer.com/static-content/images/404/art%253A10.1007%252
Fs11306-014-0721-3/MediaObjects/11306_2014_721_Fig3_HTML.gif

 

Fig. 3

Fatty acid oxidation and ETC _Fig3

Fatty acid oxidation and ETC _Fig3

 

Sampling reveals different utilization of oxidative phosphorylation by the

  • generated models.

Different distributions are observed for the CCRF-CEM model (red) and the Molt-4 model (blue).

  • Molt-4 has higher  median  flux through ETC reactions II–IV.

The table provides the median values  of the sampling results. Negative values in the histograms and in the table describe

  • reversible reactions with flux in the reverse direction.

Both models lack Complex I of the ETC because of constraints

  • arising from the mapping of transcriptomic data.

Electron transfer flavoprotein and

  • electron transfer flavoprotein–ubiquinone oxidoreductase
  •  both also carry higher flux in the Molt-4 model

 

2.1.6 Experimental validation of energy and redox status of CCRF-CEM and Molt-4 cells

Cancer cells have to balance their needs

  •  for energy and biosynthetic precursors, and they have
  • to maintain redox homeostasis to proliferate (Cairns et al. 2011).

We conducted enzymatic assays of cell lysates to measure levels and/or ratios of

  • ATP,
  • NADPH + NADP,
  • NADH + NAD, and
  • glutathione.

These measurements were used to provide support for

  • the in silico predicted metabolic differences (Fig. 4).

Additionally, an Oxygen Radical Absorbance Capacity (ORAC) assay was used

  • to evaluate the cellular antioxidant status (Fig. 4B).

Total concentrations of NADH + NAD, GSH + GSSG, NADPH + NADP and ATP, were higher in Molt-4 cells  (Fig. 4A).

The higher ATP concentration in Molt-4 cells could either result from

  • high production rates, or intracellular  accumulation connected to high or
  • low reactions fluxes (Fig. 4A).

Our simplified view that oxidative Molt-4 produces less ATP and was contradicted by

  • the higher ATP concentrations measured (Fig. 4L).

Yet we want to emphasize that concentrations

  • cannot be compared to flux values,
  • since we are modeling at steady-state.

NADH/NAD+ ratios for both cell lines were shifted toward NADH (Fig. 4D, E), but

  • the shift toward NADH was more pronounced in CCRF-CEM (Fig. 4E),
  • which matched  our expectation based on the higher utilization of
  • glycolysis and 2-oxoglutarate  dehydrogenase in the CCRF-CEM model (Fig. 4L).

 

Fig. 4 (not shown)

A–K  Experimentally determined ATP, NADH + NAD, NADPH + NADP, and GSH + GSSG concentrations, and ROS detoxification in the CCRF-CEM and Molt-4 cells.

L Expectations for cellular energy and redox states. Expectations are based on predicted metabolic differences of the Molt-4 and CCRF-CEM models

2.1.7 Comparison of network utilization and alteration in gene expression

With the assumption that

  • differential expression of particular genes would cause reaction flux changes,

we determined how the differences in gene expression (between CCRF-CEM and Molt-4)

  • compared to the flux differences observed in the  models.

Specifically, we checked whether the reactions associated with genes upregulated
(significantly more expressed in CCRF-CEM cells compared to Molt-4  cells)

  • were indeed more utilized by the CCRF-CEM model,

and we  checked  whether downregulated genes

  • were associated with reactions more utilized by the Molt-4 model.

The set of downregulated genes was associated with 15 reactions, and

  • the set of 49 upregulated genes was associated with 113 reactions in the models.

Reactions were defined as differently utilized

  • if the difference in flux exceeded 10 % (considering only non-loop reactions).

Of the reactions associated with upregulated genes,

  • 72.57 % were more utilized by the CCRF-CEM model, and
  • 2.65 % were more utilized by the Molt-4 model (File S1, Table S7).

In contrast, all 15 reactions associated with the 12 downregulated genes

  • were more utilized in the CCRF-CEM model (File S1, Table S8).

After this initial analysis, we approached the question from a different angle, asking

  • whether the majority of the reactions associated with each individual gene
  • upregulated in CCRF-CEM were more utilized by the CCRF-CEM model.
  •  this was the case for 77.55 % of the upregulated genes.

The majority of reactions associated with two (16.67 %) downregulated genes

  • were more utilized by the Molt-4 model.

Taken together, our comparisons of the

  • direction of gene expression with the fluxes of the two cancer cell-line models
  • confirmed that reactions associated with upregulated genes in the CCRF-CEM
    cells were generally more utilized by the CCRF-CEM model.

2.1.8 Accumulation of DEGs and AS genes at key metabolic steps

After we confirmed that most reactions associated with upregulated genes

  • were more utilized by the CCRF-CEM model,

we checked the locations of DEGs within the network. In this analysis, we paid special attention to

  • the central metabolic pathways that we had found
  • to be distinctively utilized by the two models.

Several DEGs and AS events were associated with

  • glycolysis,
  • the ETC,
  • pyruvate metabolism, and
  • the PPP (Table 1).

 

Table 1

DEGs and AS events of central metabolic and cancer-related pathways

Full lists of DEGs and AS are provided in the supplementary material.

Upregulated significantly more expressed in CCRF-CEM compared to Molt-4 cells

PPP pentose phosphate pathway, OxPhos oxidative phosphorylation, Glycolysis/gluconglycolysis/gluconeogenesis, Pyruvate met. pyruvate metabolism

Moreover, in glycolysis, the DEGs and/or AS genes

  • were associated with all three rate-limiting steps, i.e., the steps mediated by
  1. hexokinase,
  2. pyruvate kinase, and
  3. phosphofructokinase.

Of these key enzymes,

  • hexokinase 1 (Entrez Gene ID: 3098) was alternatively spliced,
  • pyruvate kinase (PKM, Entrez gene ID: 5315) was significantly more
    expressed in the CCRF-CEM cells (Table 1),

in agreement with the higher in silico predicted flux.

However, in contrast to the observed

  • higher utilization of glycolysis in the CCRF-CEM model,
  • the gene associated with the rate-limiting glycolysis step, phosphofructokinase (Entrez Gene ID: 5213),
  • was significantly upregulated in Molt-4 cells relative to CCRF-CEM cells.

This higher expression was detected for only a single isozyme, however. Two of
the three genes associated with phosphofructokinase were also subject to
alternative splicing (Table 1). In addition to the key enzymes, fructose
bisphosphate aldolase (Entrez Gene ID: 230) was also significantly

  • upregulated in Molt-4 cells relative to CCRF-CEM cells,
  • in contrast to the predicted higher utilization of glycolysis in the CCRF-CEM model.

Additionally, glucose-6P-dehydrogenase (G6PD), which catalyzes

  • the first reaction and committed step of the PPP,
  • was an AS gene (Table 1).

A second AS gene associated with

  •  the PPP reaction of the deoxyribokinase
  • was RBKS (Entrez Gene ID: 64080).

This gene is also associated with ribokinase, but ribokinase was removed

  • because of the lack of ribose uptake or secretion.

Single AS genes were associated with different complexes of the ETC (Table 1).

Literature query revealed that at least 13 genes associated with alternative

  • splicing events were mentioned previously in connection with both alternative
    splicing and cancer (File S1, Table S14), and
  • 37 genes were associated with cancer, e.g., upregulated, downregulated at the
    level of mRNA or protein, or otherwise
  • connected to cancer metabolism and signaling.

One general observation was that there was a surprising

  • accumulation of metabolite transporters among the AS.

Overall, the high incidence of

  • differential gene expression events at metabolic control points
  • increases the plausibility of the in silico predictions.

 

2.1.9 Single gene deletion

Analyses of essential genes in metabolic models have been used

  • to predict candidate drug targets for cancer cells (Folger et al. 2011).

Here, we conducted an in silico gene deletion study for all model genes to identify

  • a unique set of knock-out (KO) genes
  • for each condition-specific cell line model.

The analysis yielded 63 shared lethal KO genes and

  • distinct sets of KO genes for the CCRF-CEM model (11 genes) and the Molt-4 model (3 genes).

For three of the unique CCRF-CEM KO genes,

  • the genes were only present in the CCRF-CEM model (File S1, Table S9).

 

The essential genes for both models were then

  • related to the cell-line-specific differences in metabolite uptake and secretion (Fig. 1B).

The CCRF-CEM model

  1. needed to generate putrescine from ornithine
    (ORNDC, Entrez Gene ID: 4953)
  2. to subsequently produce 5-methylthioadenosine for secretion (Fig. 1B).
  3. S-adenosylmethioninamine produced by adenosylmethionine decarboxylase
    (arginine and proline metabolism, associated with Entrez Gene ID: 262)
  • is a substrate required for generation of 5-methylthioadenosine.

Another example of a KO gene connected to an enforced exchange reaction was

  • glutamic-oxaloacetic transaminase 1 (GOT1, Entrez Gene ID: 2805).

Without GOT1, the CCRF-CEM model was forced to secrete

  • 4-hydroxyphenylpyruvate (Fig. 1B),
  • the second product of tyrosine transaminase,
  • which is produced only by that enzyme.

 

One KO gene in the Molt-4 model (Entrez Gene ID: 26227) was associated with

  • phosphoglycerate dehydrogenase (PGDH),
  • which catalyzes the conversion of 3-phospho-d-glycerate to 3-phosphohydroxypyruvate
  • while generating NADH from NAD+.

This KO gene is particularly interesting, given

  • the involvement of this reaction in a novel pathway for ATP generation in rapidly proliferating cells
    (Locasale et al. 2011; Vander Heiden 2011; Vazquez et al. 2011).

Reactions associated with unique KO genes were in many cases utilized more by the model, in which

  • the gene KO was lethal,
  • underlining the potential importance of these reactions for the models.

Thus, single gene deletion provided unique sets of lethal genes that could be

  • specifically targeted to kill these cells.

 

3 Discussion

In the current study, we explored the possibility of

  • semi-quantitatively integrating metabolomic data with
  • the human genome-scale reconstruction to facilitate analysis.

By constructing condition-specific cell line models

  • to provide a structured framework,
  • we derived insights that could not have been obtained from data analysis alone.

We derived condition-specific cell line models

  • for CCRF-CEM and
  • Molt-4 cells

that were able to explain the observed exo-metabolomic differences (Fig. 1B).

Despite the overall similarities between the models, the analysis revealed

  • distinct usage of central metabolic pathways (Figs. 234),
  • which we validated based on experimental data and
  • differential gene expression.

The additional data sufficiently supported

  • metabolic differences in the cell lines,
  • providing confidence in the generated models and the model-based predictions.

We used the validated models

  • to predict unique sets of lethal genes
  • to identify weak links in each model.

These weak links may represent potential drug targets.

Integrating omics data with the human genome-scale reconstruction

  • provides a structured framework (i.e., pathways)
  • that is based on careful consideration of the available biochemical literature
    (Thiele and Palsson2010).

This network context can simplify omics data analysis, and

  • it allows even non-biochemical experts
  • to gain fast and comprehensive insights
  • into the metabolic aspects of omics data sets.

Compared to transcriptomic data,

  • methods for the integration and analysis of metabolomic data
  • in the context of metabolic models are less well established,

although it is an active field of research (Li et al. 2013; Paglia et al. 2012b).
In contrast to other studies, our approach emphasizes

  • the representation of experimental conditions rather than
  • the reconstruction of a generic, cell-line-specific network,
  • which would require the combination of data sets from
  • many experimental conditions and extensive manual curation.

Rather, our way of model construction allowed us to efficiently

  • assess the metabolic characteristics of cells.

Despite the fact, that only a limited number of exchanged metabolites can be

  • measured by available metabolomics platforms and
  • at reasonable time-scale,

and that pathways of measured metabolites might still be unknown to date
(File S1, Tables S2–S3), our methods have the potential

  • to reveal metabolic characteristics of cells
  • which could be useful for biomedicine and personalized health.

The reasons why some cancers respond to certain treatments and not others
remain unclear, and choosing a treatment for a specific patient is often difficult
(Vander Heiden 2011). One potential application of our approach could be the
characterization of cancer phenotypes to explore how cancer cells or other cell
types

  • with particular metabolic characteristics respond to drugs.

The generation of our condition-specific cell line models involved

  • only limited manual curation,
  • making this approach a fast way to place metabolomic data
  • into a network context.

Model building mainly involves

  • the rigid reduction of metabolite exchanges
  • to match the observed metabolite exchange pattern
  • with as few additional metabolite exchanges as possible.

It should be noted that this reduction determines,

  • which pathways can be utilized by the model.

Our approach mostly conserved the internal network redundancy. However, a

  • more significant reduction may be achieved using different data.

Generally, a trade-off exists between the reduction of the internal network and

  • the increasing number of network gaps that need to be curated
  • by using additional omics data, such as transcriptomics and proteomics.

One way to prevent the emergence of network gaps would be

  • to use mapping algorithms that conserve network functionality,
    such as GIMME (Becker and Palsson 2008).

However, several additional methods exist for the integration of
transcriptomic data (Blazier and Papin 2012), and

  • which model-building method is best depends on the available data.

Interestingly, the lack of a significant contribution of our

  • gene expression data to the reduction of network size
  • suggests that the use of transcriptomic data is not necessary
  • to identify distinct metabolic strategies;
  • rather, the integration of exo-metabolomic data alone
    may provide sufficient insight.

However, sampling of the cell line models constrained

  • according to the exo-metabolomic profiles only, or
  • increasing the cutoff for the generation of absent and present calls (p < 0.01),
  • did not yield the same insights as presented herein (File S1, Table S18).

Only recently Gene Inactivation Moderated by Metabolism, Metabolomics and
Expression (GIM(3)E) became available, which

  • enforces minimum turnover of detected metabolites
  • based on intracellular metabolomics data as well as
  • gene expression microarray data (Schmidt et al. 2013).

In contrast to this approach, we emphasized our analysis on the

  • relative differences in the exo-metabolomic data of two cell lines.

GIM(3)E constitutes another integration method when the analysis should be

  • emphasized on intracellular metabolomics data (Schmidt et al. 2013).

The metabolic differences predicted by the models are generally plausible.
Cancers are known to be heterogeneous (Cairns et al. 2011), and

  • the contribution of oxidative phosphorylation to cellular ATP production
    may vary (Zu and Guppy 2004).

Moreover, leukemia cell lines have been shown

  • to depend on glucose, glutamine, and fatty acids to varying extents
  • to support proliferation.

Such dependence may cause the cells to adapt their metabolism

  • to the environmental conditions (Suganuma et al. 2010).

In addition to identifying supporting data in the literature, we performed

  • several analyses to validate the models and model predictions.

Our expectations regarding the levels and ratios of metabolites

  • relevant to energy and redox state were largely met (Fig. 4L).

The more pronounced shift of the NADH/NAD+ ratio

  • toward NADH in the CCRF-CEM cells
  • was in agreement with the predicted Warburg phenotype (Fig. 4),
  • and the higher lactate secretion in the CCRF-CEM cells (File S2, Fig. S2)
  • implies an increase in NADH relative to NAD+
    (Chiarugi et al. 2012; Nikiforov et al. 2011), again
  • matching the known Warburg phenotype.

ROS production is enhanced in certain types of cancer (Droge 2002; Ha et al. 2000), and

  • the generation of ROS is thought to contribute to
  1. mutagenesis,
  2. tumor promotion, and
  3. tumor progression (Dreher and Junod1996; Ha et al. 2000).

However, decreased mitochondrial glucose oxidation and

  • a transition to aerobic glycolysis
  • protect cells against ROS damage during biosynthesis and cell division
    (Brand and Hermfisse1997).

The higher ROS detoxification capability in Molt-4 cells, in combination with

  • higher spermidine dismutase utilization by the Molt-4 model (Fig. 4),
  • provided a consistent picture of the predicted respiratory phenotype (Fig. 4L).

Control of NADPH maintains the redox potential through GSH and

  • protects against oxidative stress, yet
  • changes in the NADPH ratio in response to oxidative damage
  • are not well understood (Ogasawara et al.2009).

Under stress conditions, as assumed for Molt-4 cells,

  • the NADPH/NADP+ ratio is expected to decrease because of
  • the continuous reduction of GSSG (Fig. 4L), and
  • this was confirmed in the Molt-4 cells (Fig. 4).

The higher amounts of GSH found in Molt-4 cells in vitro may demonstrate

  • an additional need for ROS scavengers because of
  • a greater reliance on oxidative metabolism.

Cancer is related to metabolic reprogramming, which results from

  • alterations of gene expression and
  • the expression of specific isoforms or
  • splice forms to support proliferation
    (Cortes-Cros et al. 2013; Marin-Hernandez et al. 2009).

The gene expression differences detected between the two cell lines in this study
supported the existence of

  • metabolic differences in these cell lines, particularly because
  • key steps of the metabolic pathways central to cancer metabolism
  • seemed to be differentially regulated (Table 1).

The detailed analysis of the respective

  • differences on the pathway fluxes exceeds the scope of this study, which was to
  • demonstrate the potential of the integration of exo-metabolomic data into the network context.

We found discrepancies between differential gene regulation and

  • the flux differences between the two models as well as
  • the utilization AS gene-associated reaction.

This is not surprising, since analysis of the detailed system is required

  • to make any further assumptions on the impact that
  • the differential regulation or splicing might have on the reaction flux,
  • given that for many of the concerned enzymes isozymes exist, or
  • only one of multiple subunits of a protein complex was concerned.

Additionally, reaction fluxes are regulated by numerous post-translational factors, e.g.,

  • protein modification,
  • inhibition through proteins or metabolites,
  • alter reaction fluxes (Lenzen 2014),

which are out of the scope of constraint-based steady-state modeling.

Rather, the results of the presented  approach

  • demonstrate how the models can be used to generate
  • informed hypothesis that can guide experimental work.

The combination of our tailored metabolic models and

  • differential gene expression analysis seems well-suited
  • to determine the potential drivers
  • involved in metabolic differences between cells.

Such information could be valuable for drug discovery, especially when more

  • peripheral metabolic pathways are considered.

Statistical comparisons of gene expression data with sampling-derived flux data

  • could be useful in future studies (Mardinoglu et al. 2013).

A single-gene-deletion analysis revealed that PGDH was

  • a lethal KO gene for the Molt-4 model only.

Differences in PGDH protein levels

  • correspond to the amount of glycolytic carbon
  • diverted into glycine biosynthesis.

Rapidly proliferating cells may use an

  • alternative glycolytic pathway for ATP generation,
  • which may provide an advantage in the case of
  • extensive oxidative phosphorylation and proliferation
    (Locasale et al.2011; Vander Heiden 2011; Vazquez et al. 2011).

For breast cancer cell lines, variable dependency on

  • the expression of PGDH has already been demonstrated
    (Locasale et al. 2011).

This example of a unique KO gene demonstrates how

  • in silico gene deletion in metabolomics-driven models
  • can identify the metabolic pathways used by cancer cells.

This approach can provide valuable information for drug discovery.

In conclusion, our contextualization method produced

  • metabolic models that agreed in many ways with the validation data sets.

The analyses described in this study have great potential to reveal

  • the mechanisms of metabolic reprogramming,
  • not only in cancer cells but also in other cells affected by diseases, and
  • for drug discovery in general.

 

4.3 Analysis of the extracellular metabolome

Mass spectrometry analysis of the exo-metabolome was performed by
Metabolon®, Inc. (Durham, NC, USA) using a standardized analytical platform.
In total, 75 extracellular metabolites were detected in the initial data set for at
least 1 of the 2 cell lines (Paglia et al. 2012a). Of these metabolites, 15 were not
part of our global model and were discarded. Apart from being absent in our
global model, an independent search in HMDB (Wishart et al. 2013) revealed no
pathway information was available for most of these metabolites (File S1, Tables S2–S3).
It should be noted that metabolites e.g.,

  • N-acetylisoleucine,
  • N-acetyl-methionine or pseudouridine,

constitute protein and RNA degradation products, which were out of the scope
of the metabolic network.

Thiamin (Vitamin B1) was part of the minimal medium of essential compounds
supplied to both models.Riboflavin (Vitamin B2) and Trehalose were excluded
since these compounds cannot be produced by human cells. Erythrose and
fructose were also excluded. In contrast 46 metabolites that were part of the
global model. The data set included two different time points, which allowed us
to treat the increase/decrease of a metabolite signal between time points as

  • evidence for uptake or secretion when the change was greater than 5 %
    from what was observed in the control (File S1, Tables S2–S3).

We found 12 metabolites that were taken up by both cell lines and
10 metabolites that were commonly secreted by both cell lines over
the course of the experiment.

Molt-4 cells took up three metabolites not taken up by CCRF-CEM cells, and
secreted one metabolite not secreted by CCRF-CEM cells. Two of the three
uniquely uptaken metabolites were essential amino acids:

  1. valine and
  2. methionine.

It is unlikely that these metabolites were not taken up by the CCRF-CEM cells,
and the CCRF-CEM model was allowed to take up this metabolite. Therefore,
no quantitative constraints were applied for the sampling analysis either.
CCRF-CEM cells had

  • four unique uptaken
  • and seven unique secreted metabolites
    (exchange not detected in Molt-4 cells).

 

4.4 Network refinement based on exo-metabolic data

Despite its comprehensiveness, the human metabolic reconstruction is

  • not complete with respect to extracellular metabolite transporters
    (Sahoo et al. 2014; Thiele et al. 2013).

Accordingly, we identified metabolite transport systems

  • from the literature for metabolites that were already part of the global model,
  • but whose extracellular transport was not yet accounted for.

Diffusion reactions were included whenever a respective transporter could not be identified.

In total, 34 reactions [11 exchange reactions, 16 transport reactions and 7 demand reactions
(File S1, Table S11)] were added to Recon 2 (Thiele et al. 2013), and 2 additional reactions
were added to the global model (File S1, Table S10).

4.5 Expression profiling

Molt-4 and CCRF-CEM cells were grown in advanced RPMI 1640 and 2 mM
GlutaMax, and the cells were resuspended in medium containing DMSO
(0.67 %) at a concentration of 5 × 105 cells/mL. The cell suspension (2 mL)
was seeded in 12-well plates in triplicate. After 48 h of growth, the cells
were collected by centrifugation at 201×g for 5 min. Cell pellets were snap-frozen
in liquid N2 and kept frozen until RNA extraction and analysis by Aros
(Aarhus, Denmark).

4.6 Analysis of transcriptomic data

We used the Affymetrix GeneChip Human Exon 1.0 ST Array to measure whole
genome exon expression. We generated detection above background (DABG) calls
using ROOT (version 22) and the XPS package for R (version 11.1), with Robust
Multi-array Analysis summarization. Calls for data mapping were assigned based
on p < 0.05 as the cutoff probability to distinguish presence versus absence for
the 1,278 model genes (File S1, Table S12).

Differential gene expression and alternative splicing analyses were performed by
using AltAnalyse software (v2.02beta) with default options on the raw data files
(CEL files). The Homo sapiens Ensemble 65 database was used, probe set filtering
was kept as DABG p < 0.05, and non-log expression < 70 was used for
constitutive probe sets to determine gene expression levels. For the comparison,
CCRF-CEM was the experimental group and Molt-4 was the baseline group. The
set of DEGs between cell lines was identified based on a p < 0.05 FDR cutoff
(File S1, Table S13A–B). Alternative splicing analysis was performed on core probe sets
with a minimum alternative exon score of 2 and a maximum absolute gene
expression change of 3 because alternative splicing is a less critical factor among
highly DEGs (File S1, Table S14). Gene expression data, complete lists of DABG p-values,
DEGs and alternative splicing events have been deposited in the Gene
Expression Omnibus
 (GEO) database (Accession number: GSE53123).

 

4.7 Deriving cell-type-specific subnetworks

Transcriptomic data were mapped to the model in a manual fashion (COBRA
function: deleteModelGenes). Specifically, reactions dependent on gene products
that were called as “absent” were constrained to zero, such that fluxes through
these reactions were disabled. Submodels were extracted based on the set of
reactions carrying flux (network pruning) by running fastFVA
(Gudmundsson and Thiele 2010) after mapping the metabolomic and
transcriptomic data using the COBRA toolbox (Schellenberger et al. 2011).

 

…..

 

Electronic supplementary material

Below is the link to the electronic supplementary material.

File S1. Supplementary material 1 (XLSX 915 kb)

File S2. Supplementary material 2 (DOCX 448 kb)

References

Antonucci, R., Pilloni, M. D., Atzori, L., & Fanos, V. (2012). Pharmaceutical research and metabolomics in the newborn. Journal of Maternal-Fetal and Neonatal Medicine, 25, 22–26.PubMedCrossRef

Barrett, T., Troup, D. B., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., et al. (2011). NCBI GEO: archive for functional genomics data sets—10 years on. Nucleic Acids Research, 39, D1005–D1010.PubMedCentralPubMedCrossRef

Beck, M., Schmidt, A., Malmstroem, J., Claassen, M., Ori, A., Szymborska, A., et al. (2011). The quantitative proteome of a human cell line.Molecular Systems Biology, 7, 549.PubMedCentralPubMedCrossRef

Becker, S. A., & Palsson, B. O. (2008). Context-specific metabolic networks are consistent with experiments. PLoS Computational Biology, 4, e1000082.PubMedCentralPubMedCrossRef

Blazier, A. S., & Papin, J. A. (2012). Integration of expression data in genome-scale metabolic network reconstructions. Frontiers in Physiology, 3, 299.PubMedCentralPubMedCrossRef

Bordbar, A., Lewis, N. E., Schellenberger, J., Palsson, B. O., & Jamshidi, N. (2010). Insight into human alveolar macrophage and M. tuberculosisinteractions via metabolic reconstructions. Molecular Systems Biology, 6, 422.PubMedCentralPubMedCrossRef

Bordbar, A., & Palsson, B. O. (2012). Using the reconstructed genome-scale human metabolic network to study physiology and pathology. Journal of Internal Medicine, 271, 131–141.PubMedCentralPubMedCrossRef

Brand, K. A., & Hermfisse, U. (1997). Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB Journal, 11, 388–395.PubMed

Cairns, R. A., Harris, I. S., & Mak, T. W. (2011). Regulation of cancer cell metabolism. Nature Reviews Cancer, 11, 85–95.PubMedCrossRef

Chance, B., Sies, H., & Boveris, A. (1979). Hydroperoxide metabolism in mammalian organs. Physiological Reviews, 59, 527–605.PubMed

Chapman, E. H., Kurec, A. S., & Davey, F. R. (1981). Cell volumes of normal and malignant mononuclear cells. Journal of Clinical Pathology, 34, 1083–1090.PubMedCentralPubMedCrossRef

Chiarugi, A., Dolle, C., Felici, R., & Ziegler, M. (2012). The NAD metabolome—a key determinant of cancer cell biology. Nature Reviews Cancer, 12, 741–752.PubMedCrossRef

Cortes-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J. S., Yin, H., et al. (2013). M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proceedings of the National Academy of Sciences of the United States of America, 110, 489–494.PubMedCentralPubMedCrossRef

Dreher, D., & Junod, A. F. (1996). Role of oxygen free radicals in cancer development. European Journal of Cancer, 32a, 30–38.PubMedCrossRef

Droge, W. (2002). Free radicals in the physiological control of cell function. Physiological Reviews, 82, 47–95.PubMed

Duarte, N. C., Becker, S. A., Jamshidi, N., Thiele, I., Mo, M. L., Vo, T. D., et al. (2007). Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proceedings of the National Academy of Sciences of the United States of America, 104, 1777–1782.PubMedCentralPubMedCrossRef

Durot, M., Bourguignon, P. Y., & Schachter, V. (2009). Genome-scale models of bacterial metabolism: Reconstruction and applications. FEMS Microbiology Reviews, 33, 164–190.PubMedCentralPubMedCrossRef

Fleming, R. M., Thiele, I., & Nasheuer, H. P. (2009). Quantitative assignment of reaction directionality in constraint-based models of metabolism: Application to Escherichia coliBiophysical Chemistry, 145, 47–56.PubMedCentralPubMedCrossRef

Folger, O., Jerby, L., Frezza, C., Gottlieb, E., Ruppin, E., & Shlomi, T. (2011). Predicting selective drug targets in cancer through metabolic networks. Molecular Systems Biology, 7, 501.PubMedCentralPubMedCrossRef

Frezza, C., Zheng, L., Folger, O., Rajagopalan, K. N., MacKenzie, E. D., Jerby, L., et al. (2011). Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature, 477, 225–228.PubMedCrossRef

Ganske, F., & Dell, E. J. (2006). ORAC assay on the FLUOstar OPTIMA to determine antioxidant capacity. BMG LABTECH.

Gudmundsson, S., & Thiele, I. (2010). Computationally efficient flux variability analysis. BMC Bioinformatics, 11, 489.PubMedCentralPubMedCrossRef

Ha, H. C., Thiagalingam, A., Nelkin, B. D., & Casero, R. A, Jr. (2000). Reactive oxygen species are critical for the growth and differentiation of medullary thyroid carcinoma cells. Clinical Cancer Research, 6, 3783–3787.PubMed

Hyduke, D. R., Lewis, N. E., & Palsson, B. O. (2013). Analysis of omics data with genome-scale models of metabolism. Molecular BioSystems, 9, 167–174.PubMedCentralPubMedCrossRef

Jerby, L., & Ruppin, E. (2012). Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clinical Cancer Research,18, 5572–5584.PubMedCrossRef

Jerby, L., Shlomi, T., & Ruppin, E. (2010). Computational reconstruction of tissue-specific metabolic models: Application to human liver metabolism.Molecular Systems Biology, 6, 401.PubMedCentralPubMedCrossRef

Jerby, L., Wolf, L., Denkert, C., Stein, G. Y., Hilvo, M., Oresic, M., et al. (2012). Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Research, 72, 5712–5720.PubMedCrossRef

Lenzen, S. (2014). A fresh view of glycolysis and glucokinase regulation: History and current status. Journal of Biological Chemistry, 289, 12189–12194.PubMedCrossRef

Lewis, N. E., Nagarajan, H., & Palsson, B. O. (2012). Constraining the metabolic genotype–phenotype relationship using a phylogeny of in silico methods. Nature Reviews Microbiology, 10, 291–305.PubMedCentralPubMed

Lewis, N. E., Schramm, G., Bordbar, A., Schellenberger, J., Andersen, M. P., Cheng, J. K., et al. (2010). Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nature Biotechnology, 28, 1279–1285.PubMedCentralPubMedCrossRef

Li, S., Park, Y., Duraisingham, S., Strobel, F. H., Khan, N., Soltow, Q. A., et al. (2013). Predicting network activity from high throughput metabolomics. PLoS Computational Biology, 9, e1003123.PubMedCentralPubMedCrossRef

Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics, 43, 869–874.PubMedCentralPubMedCrossRef

Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Nookaew, I., Jacobson, P., et al. (2013). Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Molecular Systems Biology, 9, 649.PubMedCentralPubMedCrossRef

Marin-Hernandez, A., Gallardo-Perez, J. C., Ralph, S. J., Rodriguez-Enriquez, S., & Moreno-Sanchez, R. (2009). HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Reviews in Medicinal Chemistry, 9, 1084–1101.PubMedCrossRef

Mir, M., Wang, Z., Shen, Z., Bednarz, M., Bashir, R., Golding, I., et al. (2011). Optical measurement of cycle-dependent cell growth. Proceedings of the National Academy of Sciences of the United States of America, 108, 13124–13129.PubMedCentralPubMedCrossRef

Mo, M. L., Palsson, B. O., & Herrgard, M. J. (2009). Connecting extracellular metabolomic measurements to intracellular flux states in yeast. BMC Systems Biology, 3, 37.PubMedCentralPubMedCrossRef

Nikiforov, A., Dolle, C., Niere, M., & Ziegler, M. (2011). Pathways and subcellular compartmentation of NAD biosynthesis in human cells: From entry of extracellular precursors to mitochondrial NAD generation. The Journal of biological chemistry, 286, 21767–21778.PubMedCentralPubMedCrossRef

Ogasawara, Y., Funakoshi, M., & Ishii, K. (2009). Determination of reduced nicotinamide adenine dinucleotide phosphate concentration using high-performance liquid chromatography with fluorescence detection: Ratio of the reduced form as a biomarker of oxidative stress. Biological & Pharmaceutical Bulletin, 32, 1819–1823.CrossRef

Paglia, G., Hrafnsdottir, S., Magnusdottir, M., Fleming, R. M., Thorlacius, S., Palsson, B. O., et al. (2012a). Monitoring metabolites consumption and secretion in cultured cells using ultra-performance liquid chromatography quadrupole-time of flight mass spectrometry (UPLC-Q-ToF-MS).Analytical and Bioanalytical Chemistry, 402, 1183–1198.PubMedCrossRef

Paglia, G., Palsson, B. O., & Sigurjonsson, O. E. (2012b). Systems biology of stored blood cells: Can it help to extend the expiration date? Journal of Proteomics, 76, 163–167.PubMedCrossRef

Price, N. D., Schellenberger, J., & Palsson, B. O. (2004). Uniform sampling of steady-state flux spaces: Means to design experiments and to interpret enzymopathies. Biophysical Journal, 87, 2172–2186.PubMedCentralPubMedCrossRef

Reed, J. L., Famili, I., Thiele, I., & Palsson, B. O. (2006). Towards multidimensional genome annotation. Nature Reviews Genetics, 7, 130–141.PubMedCrossRef

Sahoo, S., Aurich, M. K., Jonsson, J. J., & Thiele, I. (2014). Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Frontiers in Physiology, 5, 91.PubMedCentralPubMedCrossRef

Sahoo, S., & Thiele, I. (2013). Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells. Human Molecular Genetics, 22, 2705–2722.PubMedCentralPubMedCrossRef

Schellenberger, J., & Palsson, B. O. (2009). Use of randomized sampling for analysis of metabolic networks. The Journal of biological chemistry,284, 5457–5461.PubMedCrossRef

Schellenberger, J., Que, R., Fleming, R. M., Thiele, I., Orth, J. D., Feist, A. M., et al. (2011). Quantitative prediction of cellular metabolism with constraint-based models: The COBRA Toolbox v2.0. Nature Protocols, 6, 1290–1307.PubMedCentralPubMedCrossRef

Schmidt, B. J., Ebrahim, A., Metz, T. O., Adkins, J. N., Palsson, B. O., & Hyduke, D. R. (2013). GIM3E: Condition-specific models of cellular metabolism developed from metabolomics and expression data. Bioinformatics (Oxford, England), 29, 2900–2908.CrossRef

Suganuma, K., Miwa, H., Imai, N., Shikami, M., Gotou, M., Goto, M., et al. (2010). Energy metabolism of leukemia cells: Glycolysis versus oxidative phosphorylation. Leukemia & Lymphoma, 51, 2112–2119.CrossRef

Thiele, I., & Palsson, B. O. (2010). A protocol for generating a high-quality genome-scale metabolic reconstruction. Nature Protocols, 5, 93–121.PubMedCentralPubMedCrossRef

Thiele, I., Price, N. D., Vo, T. D., & Palsson, B. O. (2005). Candidate metabolic network states in human mitochondria. Impact of diabetes, ischemia, and diet. The Journal of biological chemistry, 280, 11683–11695.PubMedCrossRef

Thiele, I., Swainston, N., Fleming, R. M., Hoppe, A., Sahoo, S., Aurich, M. K., et al. (2013). A community-driven global reconstruction of human metabolism. Nature Biotechnology, 31, 419–425.PubMedCrossRef

Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., et al. (2010). Towards a knowledge-based human protein Atlas.Nature Biotechnology, 28, 1248–1250.PubMedCrossRef

Vander Heiden, M. G. (2011). Targeting cancer metabolism: A therapeutic window opens. Nature Reviews Drug Discovery, 10, 671–684.PubMedCrossRef

Vazquez, A., Markert, E. K., & Oltvai, Z. N. (2011). Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS ONE, 6, e25881.PubMedCentralPubMedCrossRef

Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., et al. (2013). HMDB 3.0—The human metabolome database in 2013. Nucleic Acids Research, 41, D801–D807.PubMedCentralPubMedCrossRef

Zu, X. L., & Guppy, M. (2004). Cancer metabolism: Facts, fantasy, and fiction. Biochemical and Biophysical Research Communications, 313, 459–465.PubMedCrossRef

 

Read Full Post »

Summary of Translational Medicine – e-Series A: Cardiovascular Diseases, Volume Four – Part 1


Summary of Translational Medicine – e-Series A: Cardiovascular Diseases, Volume Four – Part 1

Author and Curator: Larry H Bernstein, MD, FCAP

and

Curator: Aviva Lev-Ari, PhD, RN

 

Part 1 of Volume 4 in the e-series A: Cardiovascular Diseases and Translational Medicine, provides a foundation for grasping a rapidly developing surging scientific endeavor that is transcending laboratory hypothesis testing and providing guidelines to:

  • Target genomes and multiple nucleotide sequences involved in either coding or in regulation that might have an impact on complex diseases, not necessarily genetic in nature.
  • Target signaling pathways that are demonstrably maladjusted, activated or suppressed in many common and complex diseases, or in their progression.
  • Enable a reduction in failure due to toxicities in the later stages of clinical drug trials as a result of this science-based understanding.
  • Enable a reduction in complications from the improvement of machanical devices that have already had an impact on the practice of interventional procedures in cardiology, cardiac surgery, and radiological imaging, as well as improving laboratory diagnostics at the molecular level.
  • Enable the discovery of new drugs in the continuing emergence of drug resistance.
  • Enable the construction of critical pathways and better guidelines for patient management based on population outcomes data, that will be critically dependent on computational methods and large data-bases.

What has been presented can be essentially viewed in the following Table:

 

Summary Table for TM - Part 1

Summary Table for TM – Part 1

 

 

 

There are some developments that deserve additional development:

1. The importance of mitochondrial function in the activity state of the mitochondria in cellular work (combustion) is understood, and impairments of function are identified in diseases of muscle, cardiac contraction, nerve conduction, ion transport, water balance, and the cytoskeleton – beyond the disordered metabolism in cancer.  A more detailed explanation of the energetics that was elucidated based on the electron transport chain might also be in order.

2. The processes that are enabling a more full application of technology to a host of problems in the environment we live in and in disease modification is growing rapidly, and will change the face of medicine and its allied health sciences.

 

Electron Transport and Bioenergetics

Deferred for metabolomics topic

Synthetic Biology

Introduction to Synthetic Biology and Metabolic Engineering

Kristala L. J. Prather: Part-1    <iBiology > iBioSeminars > Biophysics & Chemical Biology >

http://www.ibiology.org Lecturers generously donate their time to prepare these lectures. The project is funded by NSF and NIGMS, and is supported by the ASCB and HHMI.
Dr. Prather explains that synthetic biology involves applying engineering principles to biological systems to build “biological machines”.

Dr. Prather has received numerous awards both for her innovative research and for excellence in teaching.  Learn more about how Kris became a scientist at
Prather 1: Synthetic Biology and Metabolic Engineering  2/6/14IntroductionLecture Overview In the first part of her lecture, Dr. Prather explains that synthetic biology involves applying engineering principles to biological systems to build “biological machines”. The key material in building these machines is synthetic DNA. Synthetic DNA can be added in different combinations to biological hosts, such as bacteria, turning them into chemical factories that can produce small molecules of choice. In Part 2, Prather describes how her lab used design principles to engineer E. coli that produce glucaric acid from glucose. Glucaric acid is not naturally produced in bacteria, so Prather and her colleagues “bioprospected” enzymes from other organisms and expressed them in E. coli to build the needed enzymatic pathway. Prather walks us through the many steps of optimizing the timing, localization and levels of enzyme expression to produce the greatest yield. Speaker Bio: Kristala Jones Prather received her S.B. degree from the Massachusetts Institute of Technology and her PhD at the University of California, Berkeley both in chemical engineering. Upon graduation, Prather joined the Merck Research Labs for 4 years before returning to academia. Prather is now an Associate Professor of Chemical Engineering at MIT and an investigator with the multi-university Synthetic Biology Engineering Reseach Center (SynBERC). Her lab designs and constructs novel synthetic pathways in microorganisms converting them into tiny factories for the production of small molecules. Dr. Prather has received numerous awards both for her innovative research and for excellence in teaching.

VIEW VIDEOS

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=0

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=12

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=74

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=129

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=168

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk

 

II. Regulatory Effects of Mammalian microRNAs

Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells

in INTECH
Current Basic and Pathological Approaches to
the Function of Muscle Cells and Tissues – From Molecules to HumansLarissa Lipskaia, Isabelle Limon, Regis Bobe and Roger Hajjar
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/48240
1. Introduction
Calcium ions (Ca ) are present in low concentrations in the cytosol (~100 nM) and in high concentrations (in mM range) in both the extracellular medium and intracellular stores (mainly sarco/endo/plasmic reticulum, SR). This differential allows the calcium ion messenger that carries information
as diverse as contraction, metabolism, apoptosis, proliferation and/or hypertrophic growth. The mechanisms responsible for generating a Ca signal greatly differ from one cell type to another.
In the different types of vascular smooth muscle cells (VSMC), enormous variations do exist with regard to the mechanisms responsible for generating Ca signal. In each VSMC phenotype (synthetic/proliferating and contractile [1], tonic or phasic), the Ca signaling system is adapted to its particular function and is due to the specific patterns of expression and regulation of Ca.
For instance, in contractile VSMCs, the initiation of contractile events is driven by mem- brane depolarization; and the principal entry-point for extracellular Ca is the voltage-operated L-type calcium channel (LTCC). In contrast, in synthetic/proliferating VSMCs, the principal way-in for extracellular Ca is the store-operated calcium (SOC) channel.
Whatever the cell type, the calcium signal consists of  limited elevations of cytosolic free calcium ions in time and space. The calcium pump, sarco/endoplasmic reticulum Ca ATPase (SERCA), has a critical role in determining the frequency of SR Ca release by upload into the sarcoplasmic
sensitivity of  SR calcium channels, Ryanodin Receptor, RyR and Inositol tri-Phosphate Receptor, IP3R.
Synthetic VSMCs have a fibroblast appearance, proliferate readily, and synthesize increased levels of various extracellular matrix components, particularly fibronectin, collagen types I and III, and tropoelastin [1].
Contractile VSMCs have a muscle-like or spindle-shaped appearance and well-developed contractile apparatus resulting from the expression and intracellular accumulation of thick and thin muscle filaments [1].
Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs

Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs

 

Figure 1. Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs.

Left panel: schematic representation of calcium cycling in quiescent /contractile VSMCs. Contractile re-sponse is initiated by extracellular Ca influx due to activation of Receptor Operated Ca (through phosphoinositol-coupled receptor) or to activation of L-Type Calcium channels (through an increase in luminal pressure). Small increase of cytosolic due IP3 binding to IP3R (puff) or RyR activation by LTCC or ROC-dependent Ca influx leads to large SR Ca IP3R or RyR clusters (“Ca -induced Ca SR calcium pumps (both SERCA2a and SERCA2b are expressed in quiescent VSMCs), maintaining high concentration of cytosolic Ca and setting the sensitivity of RyR or IP3R for the next spike.
Contraction of VSMCs occurs during oscillatory Ca transient.
Middle panel: schematic representa tion of atherosclerotic vessel wall. Contractile VSMC are located in the media layer, synthetic VSMC are located in sub-endothelial intima.
Right panel: schematic representation of calcium cycling in quiescent /contractile VSMCs. Agonist binding to phosphoinositol-coupled receptor leads to the activation of IP3R resulting in large increase in cytosolic Ca calcium pumps (only SERCA2b, having low turnover and low affinity to Ca depletion leads to translocation of SR Ca sensor STIM1 towards PM, resulting in extracellular Ca influx though opening of Store Operated Channel (CRAC). Resulted steady state Ca transient is critical for activation of proliferation-related transcription factors ‘NFAT).
Abbreviations: PLC – phospholipase C; PM – plasma membrane; PP2B – Ca /calmodulin-activated protein phosphatase 2B (calcineurin); ROC- receptor activated channel; IP3 – inositol-1,4,5-trisphosphate, IP3R – inositol-1,4,5- trisphosphate receptor; RyR – ryanodine receptor; NFAT – nuclear factor of activated T-lymphocytes; VSMC – vascular smooth muscle cells; SERCA – sarco(endo)plasmic reticulum Ca sarcoplasmic reticulum.

 

Time for New DNA Synthesis and Sequencing Cost Curves

By Rob Carlson

I’ll start with the productivity plot, as this one isn’t new. For a discussion of the substantial performance increase in sequencing compared to Moore’s Law, as well as the difficulty of finding this data, please see this post. If nothing else, keep two features of the plot in mind: 1) the consistency of the pace of Moore’s Law and 2) the inconsistency and pace of sequencing productivity. Illumina appears to be the primary driver, and beneficiary, of improvements in productivity at the moment, especially if you are looking at share prices. It looks like the recently announced NextSeq and Hiseq instruments will provide substantially higher productivities (hand waving, I would say the next datum will come in another order of magnitude higher), but I think I need a bit more data before officially putting another point on the plot.

 

cost-of-oligo-and-gene-synthesis

cost-of-oligo-and-gene-synthesis

Illumina’s instruments are now responsible for such a high percentage of sequencing output that the company is effectively setting prices for the entire industry. Illumina is being pushed by competition to increase performance, but this does not necessarily translate into lower prices. It doesn’t behoove Illumina to drop prices at this point, and we won’t see any substantial decrease until a serious competitor shows up and starts threatening Illumina’s market share. The absence of real competition is the primary reason sequencing prices have flattened out over the last couple of data points.

Note that the oligo prices above are for column-based synthesis, and that oligos synthesized on arrays are much less expensive. However, array synthesis comes with the usual caveat that the quality is generally lower, unless you are getting your DNA from Agilent, which probably means you are getting your dsDNA from Gen9.

Note also that the distinction between the price of oligos and the price of double-stranded sDNA is becoming less useful. Whether you are ordering from Life/Thermo or from your local academic facility, the cost of producing oligos is now, in most cases, independent of their length. That’s because the cost of capital (including rent, insurance, labor, etc) is now more significant than the cost of goods. Consequently, the price reflects the cost of capital rather than the cost of goods. Moreover, the cost of the columns, reagents, and shipping tubes is certainly more than the cost of the atoms in the sDNA you are ostensibly paying for. Once you get into longer oligos (substantially larger than 50-mers) this relationship breaks down and the sDNA is more expensive. But, at this point in time, most people aren’t going to use longer oligos to assemble genes unless they have a tricky job that doesn’t work using short oligos.

Looking forward, I suspect oligos aren’t going to get much cheaper unless someone sorts out how to either 1) replace the requisite human labor and thereby reduce the cost of capital, or 2) finally replace the phosphoramidite chemistry that the industry relies upon.

IDT’s gBlocks come at prices that are constant across quite substantial ranges in length. Moreover, part of the decrease in price for these products is embedded in the fact that you are buying smaller chunks of DNA that you then must assemble and integrate into your organism of choice.

Someone who has purchased and assembled an absolutely enormous amount of sDNA over the last decade, suggested that if prices fell by another order of magnitude, he could switch completely to outsourced assembly. This is a potentially interesting “tipping point”. However, what this person really needs is sDNA integrated in a particular way into a particular genome operating in a particular host. The integration and testing of the new genome in the host organism is where most of the cost is. Given the wide variety of emerging applications, and the growing array of hosts/chassis, it isn’t clear that any given technology or firm will be able to provide arbitrary synthetic sequences incorporated into arbitrary hosts.

 TrackBack URL: http://www.synthesis.cc/cgi-bin/mt/mt-t.cgi/397

 

Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products

28 Nov 2013 | PR Web

Dr. Jon Rowley and Dr. Uplaksh Kumar, Co-Founders of RoosterBio, Inc., a newly formed biotech startup located in Frederick, are paving the way for even more innovation in the rapidly growing fields of Synthetic Biology and Regenerative Medicine. Synthetic Biology combines engineering principles with basic science to build biological products, including regenerative medicines and cellular therapies. Regenerative medicine is a broad definition for innovative medical therapies that will enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Regenerative therapies that are in clinical trials today may enable repair of damaged heart muscle following heart attack, replacement of skin for burn victims, restoration of movement after spinal cord injury, regeneration of pancreatic tissue for insulin production in diabetics and provide new treatments for Parkinson’s and Alzheimer’s diseases, to name just a few applications.

While the potential of the field is promising, the pace of development has been slow. One main reason for this is that the living cells required for these therapies are cost-prohibitive and not supplied at volumes that support many research and product development efforts. RoosterBio will manufacture large quantities of standardized primary cells at high quality and low cost, which will quicken the pace of scientific discovery and translation to the clinic. “Our goal is to accelerate the development of products that incorporate living cells by providing abundant, affordable and high quality materials to researchers that are developing and commercializing these regenerative technologies” says Dr. Rowley

 

Life at the Speed of Light

http://kcpw.org/?powerpress_pinw=92027-podcast

NHMU Lecture featuring – J. Craig Venter, Ph.D.
Founder, Chairman, and CEO – J. Craig Venter Institute; Co-Founder and CEO, Synthetic Genomics Inc.

J. Craig Venter, Ph.D., is Founder, Chairman, and CEO of the J. Craig Venter Institute (JVCI), a not-for-profit, research organization dedicated to human, microbial, plant, synthetic and environmental research. He is also Co-Founder and CEO of Synthetic Genomics Inc. (SGI), a privately-held company dedicated to commercializing genomic-driven solutions to address global needs.

In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed.  This research culminated with the February 2001 publication of the human genome in the journal, Science. Dr. Venter and his team at JVCI continue to blaze new trails in genomics.  They have sequenced and a created a bacterial cell constructed with synthetic DNA,  putting humankind at the threshold of a new phase of biological research.  Whereas, we could  previously read the genetic code (sequencing genomes), we can now write the genetic code for designing new species.

The science of synthetic genomics will have a profound impact on society, including new methods for chemical and energy production, human health and medical advances, clean water, and new food and nutritional products. One of the most prolific scientists of the 21st century for his numerous pioneering advances in genomics,  he  guides us through this emerging field, detailing its origins, current challenges, and the potential positive advances.

His work on synthetic biology truly embodies the theme of “pushing the boundaries of life.”  Essentially, Venter is seeking to “write the software of life” to create microbes designed by humans rather than only through evolution. The potential benefits and risks of this new technology are enormous. It also requires us to examine, both scientifically and philosophically, the question of “What is life?”

J Craig Venter wants to digitize DNA and transmit the signal to teleport organisms

https://pharmaceuticalintelligence.com/2013/11/01/j-craig-venter-wants-to-digitize-dna-and-transmit-the-signal-to-teleport-organisms/

2013 Genomics: The Era Beyond the Sequencing of the Human Genome: Francis Collins, Craig Venter, Eric Lander, et al.

https://pharmaceuticalintelligence.com/2013/02/11/2013-genomics-the-era-beyond-the-sequencing-human-genome-francis-collins-craig-venter-eric-lander-et-al/

Human Longevity Inc (HLI) – $70M in Financing of Venter’s New Integrative Omics and Clinical Bioinformatics

https://pharmaceuticalintelligence.com/2014/03/05/human-longevity-inc-hli-70m-in-financing-of-venters-new-integrative-omics-and-clinical-bioinformatics/

 

 

Where Will the Century of Biology Lead Us?

By Randall Mayes

A technology trend analyst offers an overview of synthetic biology, its potential applications, obstacles to its development, and prospects for public approval.

  • In addition to boosting the economy, synthetic biology projects currently in development could have profound implications for the future of manufacturing, sustainability, and medicine.
  • Before society can fully reap the benefits of synthetic biology, however, the field requires development and faces a series of hurdles in the process. Do researchers have the scientific know-how and technical capabilities to develop the field?

Biology + Engineering = Synthetic Biology

Bioengineers aim to build synthetic biological systems using compatible standardized parts that behave predictably. Bioengineers synthesize DNA parts—oligonucleotides composed of 50–100 base pairs—which make specialized components that ultimately make a biological system. As biology becomes a true engineering discipline, bioengineers will create genomes using mass-produced modular units similar to the microelectronics and computer industries.

Currently, bioengineering projects cost millions of dollars and take years to develop products. For synthetic biology to become a Schumpeterian revolution, smaller companies will need to be able to afford to use bioengineering concepts for industrial applications. This will require standardized and automated processes.

A major challenge to developing synthetic biology is the complexity of biological systems. When bioengineers assemble synthetic parts, they must prevent cross talk between signals in other biological pathways. Until researchers better understand these undesired interactions that nature has already worked out, applications such as gene therapy will have unwanted side effects. Scientists do not fully understand the effects of environmental and developmental interaction on gene expression. Currently, bioengineers must repeatedly use trial and error to create predictable systems.

Similar to physics, synthetic biology requires the ability to model systems and quantify relationships between variables in biological systems at the molecular level.

The second major challenge to ensuring the success of synthetic biology is the development of enabling technologies. With genomes having billions of nucleotides, this requires fast, powerful, and cost-efficient computers. Moore’s law, named for Intel co-founder Gordon Moore, posits that computing power progresses at a predictable rate and that the number of components in integrated circuits doubles each year until its limits are reached. Since Moore’s prediction, computer power has increased at an exponential rate while pricing has declined.

DNA sequencers and synthesizers are necessary to identify genes and make synthetic DNA sequences. Bioengineer Robert Carlson calculated that the capabilities of DNA sequencers and synthesizers have followed a pattern similar to computing. This pattern, referred to as the Carlson Curve, projects that scientists are approaching the ability to sequence a human genome for $1,000, perhaps in 2020. Carlson calculated that the costs of reading and writing new genes and genomes are falling by a factor of two every 18–24 months. (see recent Carlson comment on requirement to read and write for a variety of limiting  conditions).

Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products

https://pharmaceuticalintelligence.com/2013/11/28/startup-to-strengthen-synthetic-biology-and-regenerative-medicine-industries-with-cutting-edge-cell-products/

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

https://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/

Synthesizing Synthetic Biology: PLOS Collections

https://pharmaceuticalintelligence.com/2012/08/17/synthesizing-synthetic-biology-plos-collections/

Capturing ten-color ultrasharp images of synthetic DNA structures resembling numerals 0 to 9

https://pharmaceuticalintelligence.com/2014/02/05/capturing-ten-color-ultrasharp-images-of-synthetic-dna-structures-resembling-numerals-0-to-9/

Silencing Cancers with Synthetic siRNAs

https://pharmaceuticalintelligence.com/2013/12/09/silencing-cancers-with-synthetic-sirnas/

Genomics Now—and Beyond the Bubble

Futurists have touted the twenty-first century as the century of biology based primarily on the promise of genomics. Medical researchers aim to use variations within genes as biomarkers for diseases, personalized treatments, and drug responses. Currently, we are experiencing a genomics bubble, but with advances in understanding biological complexity and the development of enabling technologies, synthetic biology is reviving optimism in many fields, particularly medicine.

BY MICHAEL BROOKS    17 APR, 2014     http://www.newstatesman.com/

Michael Brooks holds a PhD in quantum physics. He writes a weekly science column for the New Statesman, and his most recent book is The Secret Anarchy of Science.

The basic idea is that we take an organism – a bacterium, say – and re-engineer its genome so that it does something different. You might, for instance, make it ingest carbon dioxide from the atmosphere, process it and excrete crude oil.

That project is still under construction, but others, such as using synthesised DNA for data storage, have already been achieved. As evolution has proved, DNA is an extraordinarily stable medium that can preserve information for millions of years. In 2012, the Harvard geneticist George Church proved its potential by taking a book he had written, encoding it in a synthesised strand of DNA, and then making DNA sequencing machines read it back to him.

When we first started achieving such things it was costly and time-consuming and demanded extraordinary resources, such as those available to the millionaire biologist Craig Venter. Venter’s team spent most of the past two decades and tens of millions of dollars creating the first artificial organism, nicknamed “Synthia”. Using computer programs and robots that process the necessary chemicals, the team rebuilt the genome of the bacterium Mycoplasma mycoides from scratch. They also inserted a few watermarks and puzzles into the DNA sequence, partly as an identifying measure for safety’s sake, but mostly as a publicity stunt.

What they didn’t do was redesign the genome to do anything interesting. When the synthetic genome was inserted into an eviscerated bacterial cell, the new organism behaved exactly the same as its natural counterpart. Nevertheless, that Synthia, as Venter put it at the press conference to announce the research in 2010, was “the first self-replicating species we’ve had on the planet whose parent is a computer” made it a standout achievement.

Today, however, we have entered another era in synthetic biology and Venter faces stiff competition. The Steve Jobs to Venter’s Bill Gates is Jef Boeke, who researches yeast genetics at New York University.

Boeke wanted to redesign the yeast genome so that he could strip out various parts to see what they did. Because it took a private company a year to complete just a small part of the task, at a cost of $50,000, he realised he should go open-source. By teaching an undergraduate course on how to build a genome and teaming up with institutions all over the world, he has assembled a skilled workforce that, tinkering together, has made a synthetic chromosome for baker’s yeast.

 

Stepping into DIYbio and Synthetic Biology at ScienceHack

Posted April 22, 2014 by Heather McGaw and Kyrie Vala-Webb

We got a crash course on genetics and protein pathways, and then set out to design and build our own pathways using both the “Genomikon: Violacein Factory” kit and Synbiota platform. With Synbiota’s software, we dragged and dropped the enzymes to create the sequence that we were then going to build out. After a process of sketching ideas, mocking up pathways, and writing hypotheses, we were ready to start building!

The night stretched long, and at midnight we were forced to vacate the school. Not quite finished, we loaded our delicate bacteria, incubator, and boxes of gloves onto the bus and headed back to complete our bacterial transformation in one of our hotel rooms. Jammed in between the beds and the mini-fridge, we heat-shocked our bacteria in the hotel ice bucket. It was a surreal moment.

While waiting for our bacteria, we held an “unconference” where we explored bioethics, security and risk related to synthetic biology, 3D printing on Mars, patterns in juggling (with live demonstration!), and even did a Google Hangout with Rob Carlson. Every few hours, we would excitedly check in on our bacteria, looking for bacterial colonies and the purple hue characteristic of violacein.

Most impressive was the wildly successful and seamless integration of a diverse set of people: in a matter of hours, we were transformed from individual experts and practitioners in assorted fields into cohesive and passionate teams of DIY biologists and science hackers. The ability of everyone to connect and learn was a powerful experience, and over the course of just one weekend we were able to challenge each other and grow.

Returning to work on Monday, we were hungry for more. We wanted to find a way to bring the excitement and energy from the weekend into the studio and into the projects we’re working on. It struck us that there are strong parallels between design and DIYbio, and we knew there was an opportunity to bring some of the scientific approaches and curiosity into our studio.

 

 

Read Full Post »


Modeling Targeted Therapy

Reporter: Larry H. Bernstein, MD, FCAP
pharmaceuticalintelligence.com/2013/03/02/modeling-targeted-therapy/

Some Perspectives on Network Modeling in Therapeutic Target Prediction
R Albert, B DasGupta and N Mobasheri
Biomedical Engineering and Computational Biology Insights 2013; 5: 17–24    http://dx.doi.org/BECBI/Albert_DasGupta_ Mobasheri
Key steps of a typical therapeutic target identification problem include synthesizing or inferring the complex network of interactions relevant to the disease, connecting this network to the disease-specific behavior, and predicting which components are key mediators of the behavior
http://www.la-press.com/Some_Perspectives_on_Network_Modeling_in_Therapeutic_Target_Prediction/

Journal of Computational Biology

Journal of Computational Biology (Photo credit: Wikipedia)

Read Full Post »


Author and Reporter: Anamika Sarkar, Ph.D.

Nitric Oxide (NO) is highly regulated in the blood such that it can be released as vasodilator when needed. The importance and pathway of Nitric Oxide has been nicely reviewed by. “Discovery of NO and its effects of vascular biology”. Other articles which are good readings for the importance of NO are  – a) regulation of glycolysis b) NO in cardiovascular disease c) NO and Immune responses Part I and Part II d) NO signaling pathways. The  effects of NO in diseased states have been reviewed by the articles – “Crucial role of Nitric Oxide in Cancer”, “Nitric Oxide and Sepsis, Hemodynamic Collapse, and the Search for Therapeutic Options”.. (Also, please see Source for more articles on NO and its significance).

Computational models are very efficient tools to understand complex reactions like NO towards physiological conditions. Among them wall shear stress is one of the major factors which is reviewed in the article – “Differential Distribution of Nitric Oxide – A 3-D Mathematical Model”.

Moreover, decrease in availability of NO can lead to many complications like pulmonary hypertension. Some of the causes of decrease in NO have been identified as clinical hypertension, right ventricular overload which can lead to cardiac heart failure, low levels of zinc and high levels of cardiac necrosis.

Sickle Cell disease patients, a hereditary disease, are also known to have decreased levels of NO which can become physiologically challenging. In USA alone, there are 90,000 people who are affected by Sickle cell disease.

Sickle cell disease is breakage of red blood cells (RBC) membrane and resulting release of the hemoglobin (Hb) into blood plasma. This process is also known as Hemolysis. Sickle cell disease is caused by single mutation of Hb which changes RBC from round shape to sickle or crescent shapes (Figure 1).

Image

Figure 1 (A) shows normal red blood cells flowing freely through veins. The inset shows a cross section of a normal red blood cell with normal hemoglobin. Figure 1 (B) shows abnormal, sickled red blood cells The inset image shows a cross-section of a sickle cell with long polymerized HbS strands stretching and distorting the cell shape. Image Source: http://en.wikipedia.org/wiki/Sickle-cell_disease

Sickle Cell RBCs has much shorter life span of 10-20 days when compared with normal RBCs 100-120 days lifespan. Shorter life span of Sickle cell disease RBC’s are compensated by bone marrow generation of new RBCs. However, many times new blood generation cannot cope with the small life span of Sickle cell RBCs and causes pathological condition of Anemia.

RBCs generally breakdown and release Hbs in blood plasma after they reach their end of life span. Thus, in case of Sickle cell disease, there is more cell free Hb than normal. Furthermore, it is known that NO has a very high affinity towards Hbs, which is one of the ways free NO is regulated in blood. As a result presence of larger amounts of cell free Hb in Sickle cell disease lead to less availability of NO.

However, the question remained “what is the quantitative relationship between cell free Hb and depletion of NO. Deonikar and Kavdia (J. Appl. Physiol., 2012) addressed this question by developing a 2 dimensional Mathematical Model of a single idealized arteriole, with different layers of blood vessels diffusing nutrients to tissue layers (Figure 2:  Deonikar and Kavdia Figure 1).

Image

cell free Hb in 2 dimensional representations of blood vessels.

The authors used steady state partial differential equation of circular geometry to represent diffusion of NO in blood and in tissues. They used first and second order biochemical reactions to represent the reactions between NO and RBC and NO autooxidation processes. Some of their reaction model parameters were obtained from literature, rest of them were fitted to experimental results from literature. The model and its parameters are explained in the previously published paper by same authors Deonikar and Kavdia, Annals of Biomed., 2010. The authors found that the reaction rate between NO and RBC is 0.2 x 105, M-1 s-1 than 1.4 x 105, M-1 s-1 as reported before by Butler et.al., Biochim. Biophys. Acta, 1998.

Their results show that even small increase in cell free Hb, 0.5uM, can decrease NO concentrations by 3-7 folds approximately (comparing Fig1(b) and 1(d) of Deonikar and Kavdia, 2012, as shown in Figure 2 of this article). Moreover, their mathematical analysis shows that the increase in diffusion resistance of NO from vascular lumen to cell free zone has no effect on NO distribution and concentration with available levels of cell free Hb.

Deonikar and Kavdia’s mathematical model is a simple representation of actual physiological scenario. However, their model results show that for Sickle cell disease patients, decrease in levels of bioavailable NO is an attribute to cell free Hb, which is in abundant for these patients. Their results show that small increase by 0.5 uM in cell free Hb can cause large decrease in NO concentrations.

These interesting insights from the model can help in further understanding in the context of physiological conditions, by replicating experiments in-vivo and then relating them to other known diseases of Sickle cell disease patients like Anemia, Pulmonary Hypertension. Further, drugs can be targeted towards decreasing free cell Hbs to keep balance in availability of NO, which in turn may help in other related disease like Pulmonary Hypertension of Sickle Cell disease patients.

Sources:

Deonikar and Kavdia (2012) :http://www.ncbi.nlm.nih.gov/pubmed/22223452

Previous model explaining mathematical representation and parameters used in the model :Deonikar and Kavdia, Annals of Biomed., 2010.

Previous paper stating reaction rate of Hb and NO: Butler et.al., Biochim. Biophys. Acta, 1998.

Causes of decrease in NO

Clinical Hypertension : http://www.ncbi.nlm.nih.gov/pubmed/11311074

Right ventricular overload : http://www.ncbi.nlm.nih.gov/pubmed/9559613

Low levels of zinc and high levels of cardiac necrosis : http://www.ncbi.nlm.nih.gov/pubmed/11243421

Sickle Cell Source:

http://en.wikipedia.org/wiki/Sickle-cell_disease

http://www.nhlbi.nih.gov/health/health-topics/topics/sca/

NO Source:

Differential Distribution of Nitric Oxide – A 3-D Mathematical Model:

Discovery of NO and its effects of vascular biology

Nitric Oxide has a ubiquitous role in the regulation of glycolysis -with a concomitant influence on mitochondrial function

Nitric oxide: role in Cardiovascular health and disease

NO signaling pathways

Nitric Oxide and Immune Responses: Part 1

Nitric Oxide and Immune Responses: Part 2

Statins’ Nonlipid Effects on Vascular Endothelium through eNOS Activation

https://pharmaceuticalintelligence.com/2012/10/08/statins-nonlipid-effects-on-vascular-endothelium-through-enos-activation/

Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography

Nitric Oxide, Platelets, Endothelium and Hemostasis

Crucial role of Nitric Oxide in Cancer

The rationale and use of inhaled NO in Pulmonary Artery Hypertension and Right Sided Heart Failure

Nitric Oxide and Sepsis, Hemodynamic Collapse, and the Search for Therapeutic Options

NO Nutritional remedies for hypertension and atherosclerosis. It’s 12 am: do you know where your electrons are?

Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?

Endothelial Function and Cardiovascular Disease

Interaction of Nitric Oxide and Prostacyclin in Vascular Endothelium

Endothelial Dysfunction, Diminished Availability of cEPCs,  Increasing  CVD Risk – Macrovascular Disease – Therapeutic Potential of cEPCs

Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production

 

Read Full Post »

Older Posts »